EICHORPublic-registry site landscape for NCT06062069, “A Study of CT-868 in Type 1 Diabetes Mellitus”, a Overweight study sponsored by Carmot Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT06062069 (registry record) |
| Study title | A Study of CT-868 in Type 1 Diabetes Mellitus |
| Official title | A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of CT-868 Administered for 16 Weeks to Overweight and Obese Adult Participants With Type 1 Diabetes Mellitus |
| Sponsor | Carmot Therapeutics, Inc. |
| Condition(s) | Overweight; Obese; Type 1 Diabetes Mellitus |
| Phase | PHASE2 |
| Listed sites | 22 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT06062069.
Eichor generates a preliminary site-risk snapshot for NCT06062069 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Overweight trials
← Eichor home · All tracked trials · Overweight studies · Weekly briefs
